Clinical Trials Directory

Trials / Unknown

UnknownNCT04963634

Research of Biomarkers Associated With the Diagnosis and Severity of Bradykinin Angioedema

Status
Unknown
Phase
Study type
Observational
Enrollment
110 (estimated)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The unpredictable nature of the attacks is one of the essential characteristics of bradykinin angioedema. The two main difficulties for physicians managing a patient with bradykinin angioedema are to make the diagnosis and anticipate the severity. Biomarkers can be used to diagnose, guide treatment, or predict the severity of a disease. However, the identification of biomarkers is currently difficult in bradykinin both for diagnosis and prognosis. While measurement of C4 and C1 inhibitor (quantitative and functional assays) allows the diagnosis of bradykinin angioedema due to C1 inhibitor deficiency, whether genetic or acquired, many patients with normal C1 inhibitor bradykinin angioedema, either hereditary or acquired, are still difficult to diagnose. For patients with hereditary angioedema with C1-inhibitor deficiency, there is no biomarker currently available to predict the severity. Any biomarker that could improve the diagnosis on the one hand, and improve the prediction of the frequency and severity of the response to treatment on the other hand, would obviously be extremely useful. The aim of our study is to assess the existence possible biomarkers for diagnosis and prognosis of bradykinin angioedema.

Conditions

Interventions

TypeNameDescription
OTHERBiobankingFor patients included in BRADYDIAG study, 2 blood samples will be collected at enrollment (for group 1: bradykinin angioedema and for group 2: histamine-mediated angioedema) and at 1 year visit (for group 1 only: bradykinin angioedema).

Timeline

Start date
2022-01-22
Primary completion
2026-01-01
Completion
2026-01-01
First posted
2021-07-15
Last updated
2022-04-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04963634. Inclusion in this directory is not an endorsement.